SATISFY‐JP, a Phase II Multicenter Open‐label Study on Satralizumab, an Anti‐il‐6 Receptor Antibody, Use for the Treatment of Pulmonary Arterial Hypertension in Patients with an Immune‐responsive‐phenotype: Study Protocol
PULMONARY CIRCULATION（2023）
Key words
antibody,artificial intelligence clustering,IL6R-blocking therapy,precision medicine,pulmonary artery hypertension
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined